EP0995751A3
Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
Abstract
There is provided compounds of formula IA and of formula IB, wherein R1, R2, R3, R4 and A have meanings given in the description, which are useful in the curative and prophylactic treatment of a medical condition for which inhibition of a cyclic guanosine 3',5'-monophosphate phosphodiesterase (e.g. cGMP PDE5) is desired.
Term
Term ended
Projected expiry passed 15 October 2019, 6.9 years ago.
- Priority
- Filed
- Published
- Projected expiry
- Today
1 sheet
Sheet 1
Every citation, both waysCites: the store holds 10 of 11
| Document | Relation | Office | Category | Cited during | Relevant claims |
|---|---|---|---|---|---|
| EP0636626A1 | Cites | European Patent Office (EPO) | YX | Search report | 1-16,19,20 |
| EP0812845A1 | Cites | European Patent Office (EPO) | Y | Search report | 17,18 |
| WO9307149A1 | Cites | World Intellectual Property Organization (WIPO) | XDY | Search report | 1-16 |
| WO9400453A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-16,19,20 |
| WO9428902A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-16,19,20 |
| WO9616657A1 | Cites | World Intellectual Property Organization (WIPO) | XDY | Search report | 1-16 |
| WO9628429A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-16 |
| WO9628448A1 | Cites | World Intellectual Property Organization (WIPO) | Y | Search report | 1-16 |
| WO9849166A1 | Cites | World Intellectual Property Organization (WIPO) | PX | Search report | 1-16,19,20,17,18 |
| WO9954333A1 | Cites | World Intellectual Property Organization (WIPO) | E | Search report | 1-20 |
14 members in 9 offices
Priority claims5
| Document | Office | Kind | Date |
|---|---|---|---|
| 9823103 | United Kingdom | A | |
| 9823103 | United Kingdom | A | |
| 9823103 | United Kingdom | – | |
| 9823103 | – | – | – |
| GB19980023103 | – | – | – |
Members14
| Document | Office | Kind | |
|---|---|---|---|
| GB9823103D0 | United Kingdom | D0 | |
| CA2287562A1 | Canada | A1 | |
| EP0995751A2 | European Patent Office (EPO) | A2 | |
| JP2000128884A | Japan | A | |
| BR9905109A | Brazil | A | |
| EP0995751A3This record | European Patent Office (EPO) | A3 | |
| US6407114B1 | United States of America | B1 | |
| EP0995751B1 | European Patent Office (EPO) | B1 | |
| JP3670908B2 | Japan | B2 | |
| AT298753T | Austria | T | |
| ATE298753T1 | Austria | T1 | |
| DE69925970D1 | Germany | D1 | |
| ES2243037T3 | Spain | T3 | |
| DE69925970T2 | Germany | T2 |
53 legal events, as 6 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Fr: translation filedET | ET | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents actLapsedNLV1 | NLV1 | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| Corresponds to:REF | REF | EP | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Designation fees paidAT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SEAKX | AKX | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAL;LT;LV;MK;RO;SIAX | AX | EP | |
| Search report despatchedORIGINAL CODE: 0009013PUAL | PUAL | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAL;LT;LV;MK;RO;SIAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 0995751
- Publication, DOCDB
- 0995751
- Publication, EPODOC
- EP0995751
- Application
- 99308158
- Application, DOCDB
- 99308158
- Application, EPODOC
- EP19990308158
Titles3
- German
- Pyrazolopyrimidinone cGMP PDE5 Inhibitoren zur Behandlung der sexuellen Dysfunktion
- English
- Pyrazolopyrimidinone cGMP PDE5 inhibitors for the treatment of sexual dysfunction
- French
- Inhibiteurs de cGMP PDE5 de pyrazolopyrimidinone servant à traiter le dysfonctionnement sexuel
Classification
- CPC, 19
- C07D487/04
- A61P1/00
- A61P11/00
- A61P11/06
- A61P13/00
- A61P13/08
- A61P13/10
- A61P15/10
- A61P17/00
- A61P17/06
- A61P17/14
- A61P25/00
- A61P25/28
- A61P27/06
- A61P35/04
- A61P43/00
- A61P9/00
- A61P9/10
- A61P9/12
- IPC, 21
- A61K31 519
- A61K31 5377
- A61P1 00
- A61P9 00
- A61P9 10
- A61P9 12
- A61P11 00
- A61P11 06
- A61P13 00
- A61P13 08
- A61P13 10
- A61P15 10
- A61P17 00
- A61P17 06
- A61P17 14
- A61P25 00
- A61P25 28
- A61P27 06
- A61P35 04
- A61P43 00
- C07D487 04
Designated states25
- Contracting states, 19
- Austria
- Belgium
- Switzerland
- Cyprus
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden
- Extension states, 6
- Albania
- Lithuania
- Latvia
- North Macedonia
- Romania
- Slovenia